


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1.-10. (Canceled)

11. (Previously presented) An apoptotic composition that induces apoptosis by binding to a Bcl-2 family member protein and preferentially inducing apoptosis in a cell that over-expresses the Bcl-2 family member protein, the composition having the following formula II,



having an absolute configuration of [2R, 3R, 4S, 7S, 8R], and wherein

R<sub>1</sub> is hydrogen, a C<sub>1</sub>-C<sub>8</sub> linear or branched alkane, hydroxyl, a C<sub>1</sub>-C<sub>8</sub> hydroxyalkane, amino, a C<sub>1</sub>-C<sub>8</sub> di- or tri-amine, a C<sub>1</sub>-C<sub>8</sub> amide, a C<sub>1</sub>-C<sub>8</sub> carboxylic acid, or a substituted alkyl group;

R<sub>2</sub> is hydrogen, a C<sub>1</sub>-C<sub>8</sub> linear or branched alkane, hydroxyl, a C<sub>1</sub>-C<sub>8</sub> hydroxyalkane, amino, a C<sub>1</sub>-C<sub>8</sub> di- or tri-amine, a C<sub>1</sub>-C<sub>8</sub> amide, a C<sub>1</sub>-C<sub>8</sub> carboxylic acid, or a substituted alkyl group;

R<sub>3</sub> is hydrogen, a C<sub>1</sub>-C<sub>8</sub> linear or branched alkane, hydroxyl, a C<sub>1</sub>-C<sub>8</sub> hydroxyalkane, amino, a C<sub>1</sub>-C<sub>8</sub> di- or tri-amine, a C<sub>1</sub>-C<sub>8</sub> amide, a C<sub>1</sub>-C<sub>8</sub> carboxylic acid, or a substituted alkyl group;

R<sub>4</sub> is hydrogen, a C<sub>1</sub>-C<sub>8</sub> linear or branched alkane, a C<sub>1</sub>-C<sub>8</sub> hydroxyalkane, or a substituted alkyl group;

R<sub>5</sub> is hydrogen, a C<sub>1</sub>-C<sub>8</sub> linear or branched alkane, hydroxyl, a C<sub>1</sub>-C<sub>8</sub> hydroxyalkane, amino, a C<sub>3</sub>-C<sub>8</sub> di- or tri-alkylamine, a C<sub>1</sub>-C<sub>8</sub> carboxylic acid, a C<sub>2</sub>-C<sub>8</sub> amide, or a substituted alkyl group; and

R<sub>6</sub> is hydrogen, a C<sub>1</sub>-C<sub>8</sub> linear or branched alkane, hydroxyl, a C<sub>1</sub>-C<sub>8</sub> hydroxyalkane, amino, a C<sub>1</sub>-C<sub>8</sub> di- or tri-amine, a C<sub>1</sub>-C<sub>8</sub> amide, a C<sub>1</sub>-C<sub>8</sub> carboxylic acid, or a substituted alkyl group.


12. (Previously presented) The composition of claim 11, further comprising a pharmaceutically acceptable carrier.

13. (Previously presented) The composition of claim 11 for use in treating an apoptosis-associated disease in a subject in need thereof.

14. (Canceled)

15. - 20. (Canceled)

21. (Previously presented) A method for treating a subject having an apoptosis-associated disease, comprising administering to the subject a therapeutically effective amount of a composition, wherein the composition comprises an antimycin of the following formula, and having an absolute configuration of [2R, 3R, 4S, 7S, 8R]:



wherein R<sub>1</sub> is hydrogen, a C<sub>1</sub>-C<sub>8</sub> linear or branched alkane, hydroxyl, a C<sub>1</sub>-C<sub>8</sub> hydroxyalkane, amino, a C<sub>1</sub>-C<sub>8</sub> di- or tri-amine, a C<sub>1</sub>-C<sub>8</sub> amide, a C<sub>1</sub>-C<sub>8</sub> carboxylic acid, or a substituted alkyl group;

R<sub>2</sub> is hydrogen, a C<sub>1</sub>-C<sub>8</sub> linear or branched alkane, hydroxyl, a C<sub>1</sub>-C<sub>8</sub> hydroxyalkane, amino, a C<sub>1</sub>-C<sub>8</sub> di- or tri-amine, a C<sub>1</sub>-C<sub>8</sub> amide, a C<sub>1</sub>-C<sub>8</sub> carboxylic acid, or a substituted alkyl group;

R<sub>3</sub> is hydrogen, a C<sub>1</sub>-C<sub>8</sub> linear or branched alkane, hydroxyl, a C<sub>1</sub>-C<sub>8</sub> hydroxyalkane, amino, a C<sub>1</sub>-C<sub>8</sub> di- or tri-amine, a C<sub>1</sub>-C<sub>8</sub> amide, a C<sub>1</sub>-C<sub>8</sub> carboxylic acid, or a substituted alkyl group;

R<sub>4</sub> is hydrogen, a C<sub>1</sub>-C<sub>8</sub> linear or branched alkane, hydroxyl, a C<sub>1</sub>-C<sub>8</sub> carboxylic acid, or a substituted alkyl group;

R<sub>5</sub> is hydrogen, a C<sub>1</sub>-C<sub>8</sub> linear or branched alkane, hydroxyl, a C<sub>1</sub>-C<sub>8</sub> hydroxyalkane, amino, a C<sub>1</sub>-C<sub>8</sub> di- or tri-alkylamine, a C<sub>1</sub>-C<sub>8</sub> amide, a C<sub>1</sub>-C<sub>8</sub> carboxylic acid, or a substituted alkyl group; and

R<sub>6</sub> is hydrogen, a C<sub>1</sub>-C<sub>8</sub> linear or branched alkane, hydroxyl, a C<sub>1</sub>-C<sub>8</sub> hydroxyalkane, amino, a C<sub>1</sub>-C<sub>8</sub> di- or tri-amine, a C<sub>1</sub>-C<sub>8</sub> amide, a C<sub>1</sub>-C<sub>8</sub> carboxylic acid, or a substituted alkyl group.

22. (Original) The method of claim 21, wherein the antimycin derivative is 2-methoxy ether antimycin A or A<sub>3</sub>.

23. (Canceled)

24. (Previously presented) The method of claim 21, wherein the subject is human.

25. (Previously presented) The method of claim 21, further comprising administering a pharmaceutical carrier.

26. (Previously presented) The method of claim 21, wherein the administration is intravenous, subcutaneous, intramuscular, intradermal, transdermal, intrathecal, intracerebral, intraperitoneal, epidural or oral.